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ABSTRACT
Increased glutamate availability in the spinal cord and primary
afferent nerves plays an important role in acute and chronic
pain. Afferent ectopic discharges from the site of nerve injury
constitute a source of abnormal sensory input to the spinal
dorsal horn. The ectopic afferent activity is largely responsible
for the development of hypersensitivity of dorsal horn neurons
and neuropathic pain. Inhibition of glutamate carboxypeptidase
II (GCP II) reduces glutamate release generated from N-acetyl-
aspartyl-glutamate in nerve tissues and may have an analgesic
effect on neuropathic pain. In the present study, we determined
the effect of a GCP II inhibitor, 2-(phosphono-methyl)-pen-
tanedioic acid (2-PMPA), on allodynia and ectopic afferent dis-
charges in an animal model of neuropathic pain. Neuropathic
pain was induced by partial ligation of the left sciatic nerve in
rats. Tactile allodynia was assessed using von Frey filaments
applied to the plantar surface of the injured hindpaw. Single-
unit activity of ectopic discharges was recorded from the sci-
atic nerve proximal to the site of ligation. Intravenous injection
of 50 to 100 mg/kg 2-PMPA significantly reduced allodynia in a
dose-dependent manner. Furthermore, 2-PMPA dose-depen-
dently attenuated the ectopic discharge activity of injured sci-
atic afferent nerves. At a dose of 100 mg/kg, 2-PMPA signifi-
cantly inhibited the ectopic activity from 14.7  2.1 to 4.4  0.5
impulses/s without altering the conduction velocity of afferent
nerves. Therefore, these data suggest that the antiallodynic
effect of 2-PMPA may be mediated, at least in part, by inhibition
of ectopic afferent discharges at the site of nerve injury.
Peripheral nerve injury elicits a number of electrophysio-
logical and molecular changes in axons proximal to the injury
site as well as their neuronal cell bodies of origin. Unlike
sensory nerve endings, the mature afferent axons normally
are not capable of generating sustained discharges, even
when strong natural stimuli are applied. However, a sub-
stantial proportion of afferents develop an ectopic repetitive
firing capability in the region of injury after nerve injury
(Devor, 1991; Devor et al., 1993). Ectopic afferent discharges
from the site of nerve injury constitute a source of abnormal
sensory input to the spinal dorsal horn (Kajander et al., 1992;
Matzner and Devor, 1994). There is a growing appreciation
that peripheral and central neuroplasticity are not mutually
exclusive, but interact extensively to reinforce the patholog-
ical changes that contribute to chronic pain (Campbell et al.,
1988; Devor et al., 1993; Sheen and Chung, 1993). The ec-
topic afferent activity is largely responsible for the develop-
ment of hypersensitivity of spinal cord dorsal horn neurons
and the hyperalgesia and allodynia (abnormal pain sensation
in response to innocuous stimuli) associated with neuro-
pathic pain in rats (Kajander et al., 1992; Matzner and De-
vor, 1994; Yoon et al., 1996). Clinical studies also provide
strong evidence that the ectopic discharges from afferent
nerves are a source of ongoing spontaneous pain, and this
abnormal afferent activity dynamically maintains a state of
central hypersensitivity that underlies evoked-pain syn-
dromes such as allodynia and hyperalgesia in patients with
painful neuropathies (Gracely et al., 1992; Campero et al.,
1998). Thus, drugs capable of suppressing the ectopic affer-
ent activity may provide an effective therapy for the treat-
ment of neuropathic pain. In this regard, the analgesic effect
of anticonvulsants may be mediated partly by their action on
ectopic afferent discharges (Yaari and Devor, 1985; Pan et
al., 1999).
Mechanisms underlying the generation of ectopic dis-
charges from injured afferents are complex and likely involve
the interaction between endogenous chemicals and ion chan-
nels. After nerve injury, the anterograde transport of pro-
teins and neurotransmitters results in accumulation at the
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site of nerve injury, which may be responsible for the gener-
ation of ectopic discharges to cause chronic pain (Burchiel
and Ochoa, 1991; Devor, 1991). Increased glutamate avail-
ability in the peripheral nerve has been shown to play a role
in nociception (Davidson et al., 1997; Carlton and Coggeshall,
1999; Du et al., 2001). N-Acetyl-aspartyl-glutamate (NAAG)
is hydrolyzed by the neuropeptidase glutamate carboxypep-
tidase II (GCP II; also termed N-acetylated -linked acidic
dipeptidase) to liberate N-acetyl-aspartate and glutamate.
Both NAAG and GCP II are present in the peripheral nerve
and dorsal root ganglia, especially in astrocytic glial cells and
nonmyelinating Schwann cells (Berger et al., 1995; Berger
and Schwab, 1996). Thus, an important source of glutamate
in the peripheral nerve after nerve injury could be derived
from NAAG through stimulation of GCP II. 2-(Phosphono-
methyl)-pentanedioic acid (2-PMPA) is a potent and selective
GCP II inhibitor (Jackson et al., 1996), which reduces gluta-
mate accumulation and increases NAAG in the brain tissue
in a rat model of cerebral ischemia (Slusher et al., 1999).
NAAG itself could additionally reduce glutamate release via
its action on mGlu3 receptors (Slusher et al., 1999). Inhibi-
tion of spinal GCP II attenuates nociception caused by in-
flammation in rats (Yamamoto et al., 2001a,b). We reasoned
that inhibition of GCP II may ultimately reduce glutamate
levels in the nerve tissue and produce an analgesic effect on
neuropathic pain. The major objective of the present study
was to examine the effect of 2-PMPA on allodynia and the
ectopic discharge activity from the injured afferent nerve in
an animal model of neuropathic pain.
Materials and Methods
Male rats (Harlan Sprague-Dawley, Indianapolis, IN) weighing
225 to 250 g were used in this study. Under halothane anesthesia,
the left sciatic nerve was exposed and isolated at the midthigh, and
one-third to one-half of the nerve was ligated tightly with a 5.0 silk
suture, according to the method described previously (Seltzer et al.,
1990). The animals were allowed to recover for 10 to 14 days after
nerve injury. Then, the right jugular vein was cannulated with
polyethylene-50 tubing, and the catheter was externalized to the
back of the neck under halothane anesthesia. The rats were used for
behavioral testing and electrophysiological studies after recovery for
at least 3 days after cannulation. We and others have shown that
stable tactile allodynia develops within 1 week after nerve ligation
and lasts for at least 4 weeks (Seltzer et al., 1990; Pan et al., 1999).
Thus, all of the final studies were conducted between 2 and 4 weeks
after sciatic nerve ligation. The surgical preparations and experi-
mental protocols were approved by the Animal Care and Use Com-
mittee of the Penn State University College of Medicine and con-
formed to National Institutes of Health guidelines on the ethical use
of animals. All efforts were made to minimize both the suffering and
number of animals used.
Behavioral Assessment of Tactile Allodynia. To evaluate the
mechanical sensitivity of the injured hindpaw, rats were placed in
individual plastic boxes on a mesh floor and allowed to acclimate for
30 min. A series of calibrated von Frey filaments (Stoelting Co.,
Wood Dale, IL) were applied perpendicularly to the plantar surface
of the left hindpaw with sufficient force to bend the filaments for 6 s.
Brisk withdrawal or paw flinching was considered as a positive
response. In the absence of a response, the filament of next greater
force was applied. In the presence of a response, the filament of next
lower force was applied. The tactile stimulus producing a 50% like-
lihood of withdrawal response was calculated by using the “up-down”
method, as described in detail previously (Chaplan et al., 1994; Pan
et al., 1999). Each trial was repeated two to three times at approx-
imately 2-min intervals. Three separate groups of animals, each
consisting of eight rats, were used for behavioral studies. After
obtaining a consistent baseline, a single dose (25, 50, or 100 mg/kg)
of 2-PMPA was injected intravenously. The paw-withdrawal thresh-
old was determined every 15 to 30 min up to 3 h after injection of
2-PMPA. Motor dysfunction was evaluated by testing the ability of
the animals to stand and ambulate in a normal posture and to place
and step with the hindpaw. We assessed the motor function in a
simple manner by grading the ambulation behavior of rats as fol-
lows: 2  normal; 1  limping; 0  paralyzed.
Recording of Single-Unit Activity of Afferent Nerves. Allo-
dynic conditions were first verified in all rats before afferent nerve
recording experiments. Rats were anesthetized with an intraperito-
neal injection of sodium phenobarbital (45 mg/kg). The right jugular
vein and left carotid artery were cannulated for administering drugs
and monitoring the blood pressure, respectively. The trachea was
cannulated and the rat was ventilated artificially with a respirator
(SAR-830; IITC Inc./Life Science, Woodland Hills, CA). Arterial
blood gases were analyzed with a blood gas analyzer and maintained
within physiological limits. Throughout the experiment, body tem-
perature was maintained in the range of 37–38°C with a circulating
water heating pad and heat lamps. The fascia and sheath overlying
the left sciatic nerve were removed carefully. The nerve then was
draped on a platform and covered with warm mineral oil. Small
nerve filaments were teased gently from the nerve segment proximal
to the ligated site under an operating microscope (model M900; D. F.
Vasconcellos S.A., Sào Paulo, Brazil). Single-unit afferent nerve ac-
tivity was recorded with a bipolar stainless electrode. The filaments
in the distal-cut end of the sciatic nerve were dissected gradually
until the single-unit activity of afferents was isolated. The action
potential of the nerve was amplified, filtered with a bandpass filter
of 100 to 1000 Hz, and monitored through an audioamplifier (model
AM8; Grass Instruments, West Warwick, RI) and a storage oscillo-
scope (TDS 210; Tektronix, Wilsonville, OR). The neurogram was
recorded on a thermal-sensitive recorder (model K2G; Astro-Med,
West Warwick, RI). The single-unit afferent was identified initially
by examining the wave form and the spike amplitude on the oscillo-
scope at a rapid sweep speed, as well as by checking the recorded
sound frequency related to each spike activity. Furthermore, the
signals were digitized at a sampling rate of 20 kHz and recorded into
a Pentium computer through an analog-to-digital interface card for
subsequent off-line analysis. An amplitude threshold was set for the
recorded action potential of nerve fibers. When an event was de-
tected, the associated wave form (6 ms) was extracted and displayed
continuously in a separate software oscilloscope window. Single-unit
recording was ensured by checking the constancy of the shape and
polarity of the displayed spike wave form. Discharge frequency was
quantified using a software program (Experimental Workbench;
DataWave Technology Inc., Longmont, CO).
After the spontaneous discharge activity of a single-unit afferent
was identified, the baseline discharge was recorded for 10 to 15 min.
Then, 2-PMPA was injected intravenously at the dose of 25, 50, or
100 mg/kg. We have shown previously that intravenous injection of
saline has no effect on the baseline spontaneous ectopic discharges
(Pan et al., 1999). We used the following two criteria to ensure that
the recorded activity was ectopic discharges originating from the
neuromas (Pan et al., 1999): 1) recorded nerve fibers had no receptive
field in the peripheral tissue; and 2) at the end of recordings, the
ectopic discharge activity was increased by mechanical stimulation
of the neuroma but was not altered by transecting the nerve distal to
the neuroma site. In separate normal rats, we determined whether
intravenous injection of 2-PMPA had any effect on the responses of
normal afferent fibers to mechanical stimulation, because normal
afferent fibers usually have no spontaneous discharges. After the
receptive fields of afferents were precisely located on the skin, the
conduction velocity and afferent responses to stimulation of the
receptive field with von Frey filaments were examined before and 30
min after intravenous injection of 100 mg/kg 2-PMPA.
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The conduction velocity of normal and injured afferent fibers was
measured by electrical stimulation of the sural and the sciatic nerve
proximal to the ligated site, respectively. A bipolar stimulating elec-
trode was placed distal to the recording site to electrically evoke the
action potential of the afferent (Pan et al., 1999). Conduction time
was determined by measuring the time interval from the signal of
electrical stimulation to recording of the evoked afferent’s action
potential displayed on the oscilloscope. C- and A-fiber afferents
were classified as those with a conduction velocity  2.0 and 2.0 to 15
m/s, respectively. Those with a conduction velocity  15 m/s were
considered to be A-fiber afferents.
The ectopic discharge activity of afferents was averaged during
control and for 30 to 45 min after 2-PMPA treatment. All the behav-
ioral data collected were normally distributed, as determined by the
Komogorov-Smirnov test. Thus, these data are presented as mean 
S.E.M., and parametric tests were chosen for statistical analysis.
Differences in the paw-withdrawal threshold in response to mechan-
ical stimulation before and after nerve ligation, the conduction ve-
locity, and the evoked response of normal afferents by mechanical
stimulation before and after 2-PMPA treatment were compared us-
ing Student’s paired t test. The effect of 2-PMPA on allodynia and
afferent ectopic activity was determined by repeated measures anal-
ysis of variance followed by Dunnett’s post hoc test. P  0.05 was
considered to be statistically significant.
Results
Effect of 2-PMPA on Mechanical Allodynia. Paw-with-
drawal threshold in response to application of von Frey fila-
ments before sciatic nerve ligation was 22.7  2.1 g (n  24).
The mechanical threshold decreased significantly (2.5 
0.7 g, P  0 0.05) within 7 days after nerve ligation and
remained stable for at least 3 weeks in the animals studied.
Two rats were excluded from the study because the paw-
withdrawal threshold was  8 g, 2 weeks after nerve ligation.
Intravenous injection of 25 mg/kg 2-PMPA did not signifi-
cantly change the withdrawal threshold in response to appli-
cation of von Frey filaments in eight rats. Intravenous injec-
tion of 50 (n  8) and 100 (n  8) mg/kg 2-PMPA both
significantly increased the paw-withdrawal threshold in a
dose-dependent manner (Fig. 1). 2-PMPA administration
was not associated with any overt behavioral changes, such
as sedation or agitation, in rats receiving the above doses of
2-PMPA. The motor function, assessed by testing the ani-
mals’ ability to stand and ambulate in a normal posture and
to place and step with the hindpaw, was not altered by the
2-PMPA treatment. All rats received a score of 2 after intra-
venous injection of 100 mg/kg 2-PMPA.
Electrophysiological Recording Studies. A total of 27
afferents were recorded from the injured left sciatic nerve in
27 rats. These afferents exhibited typical spontaneous burst-
ing discharge activity (Fig. 2). The conduction velocity was
measured in 19 of 27 afferents studied. There were 10 A-
fibers with a conduction velocity ranging from 3.4 to 13.8 m/s.
The 3 C-fibers had a conduction velocity of between 0.6 and
1.5 m/s. The remaining 6 afferents were A-fibers with a
conduction velocity between 18.5 and 44.8 m/s. In 7 afferent
fibers, intravenous injection of 25 mg/kg 2-PMPA did not
significantly affect the spontaneous ectopic activity (Fig. 3).
Intravenous injection of 50 (n  10) and 100 (n  10) mg/kg
of 2-PMPA both significantly decreased the spontaneous ec-
topic discharges recorded from injured sciatic afferent nerves
(Figs. 2 and 3). 2-PMPA had a similar inhibitory effect on
ectopic discharges recorded from all three types of afferent
nerves. The inhibitory effect of 2-PMPA on the ectopic dis-
charge activity lasted 60 to 90 min in all animals tested.
In 10 normal rats, intravenous injection of 100 mg/kg
2-PMPA did not alter the response of 10 normal afferent
fibers to mechanical stimulation, evoked by application of
calibrated von Frey filaments with bending forces of 2, 5, and
25 g applied to the receptive fields of the afferents (Fig. 4).
Among 10 normal afferents, there were 5 A-fibers (conduc-
tion velocity  8.4  1.7 m/s), 2 C-fibers (conduction veloc-
ity  1.1  0.4 m/s), and 3 A-fibers (conduction velocity 
26.8  3.6 m/s). We observed that 2-PMPA had no effect on
the spontaneous activity of 3 A-fibers and 2 A-fibers in
normal rats (data not shown). Intravenous injection of 100
mg/kg 2-PMPA had no effect on the conduction velocity of
these 10 afferent nerves.
Fig. 1. Time course of the effect
of intravenous injection of 25, 50,
and 100 mg/kg 2-PMPA on allo-
dynia induced by partial sciatic
nerve ligation in rats. The me-
chanical thresholds were deter-
mined by the paw-withdrawal
response to von Frey filaments.
Data are presented as means 
S.E.M. (n  8 in each group). ,
P  0.05 versus pretreatment
control.
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Discussion
The major finding of the current study is that systemic
administration of 2-PMPA attenuated allodynia and inhib-
ited the ectopic discharge activity from the injured peripheral
afferent nerve in rats. We observed that intravenous injec-
tion of 2-PMPA dose-dependently attenuated allodynia
caused by partial sciatic nerve ligation. Furthermore, we
found that the similar dose of 2-PMPA significantly inhibited
the discharge activity recorded from injured afferent fibers
but had no effect on the conduction velocity. Therefore, these
data suggest that the inhibitory action of 2-PMPA on the
generation of ectopic afferent discharges likely constitutes a
mechanism by which 2-PMPA produces an antiallodynic ef-
fect in this animal model of neuropathic pain.
GCP II is found in the brain tissue, spinal cord, dorsal root
ganglia, and nonmyelinating Schwann cells (Berger et al.,
1995; Berger and Schwab, 1996). GCP II is a membrane-
bound metallopeptidase that catabolizes NAAG to N-acetyl-
aspartate and glutamate (Robinson et al., 1987; Stauch et al.,
1989). 2-PMPA is a potent and selective GCP II inhibitor
(Jackson et al., 1996) that can reduce brain ischemic damage
by reducing local glutamate accumulation and increasing
NAAG (Slusher et al., 1999). It has been shown that 2-PMPA
inhibits spinal dorsal horn neurons in the rat inflammation
Fig. 2. Histogram (bottom panel) showing the time course of the inhibitory effect of intravenous injection of 50 mg/kg 2-PMPA on the ectopic discharge
activity from an injured sciatic afferent fiber (conduction velocity  8.4 m/s). 2-PMPA was injected at the time indicated by the arrow. Two segments
of original neurograms (top panel) were representative recordings sampled during control (a) and 30 min after (b) 2-PMPA treatment, as indicated in
the histogram. Each tracing is 30 s of recording.
Fig. 3. Summary data showing the effect of in-
travenous injection of 25 (n  7), 50 (n  10), or
100 (n  10) mg/kg 2-PMPA on the ectopic dis-
charge activity recorded from injured sciatic af-
ferent nerves in anesthetized rats. The discharge
activity of injured afferent nerves was averaged
for 5 min during the control period and for 30 min
after 2-PMPA treatment. Data are presented as
means  S.E.M. , P  0.05 versus pretreatment
control.
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and nerve injury models (Carpenter et al., 2000). Intrathecal
injection of 2-PMPA also depresses both the phase 1 and
phase 2 flinching behaviors in rats caused by formalin injec-
tion (Yamamoto et al., 2001b). In the present study, systemic
injection of 2-PMPA significantly attenuated allodynia in-
duced by sciatic nerve injury in rats. These data provide
additional evidence that GCP II inhibitors have a therapeutic
effect on neuropathic pain. Although the precise analgesic
mechanisms of 2-PMPA on neuropathic pain could not be
determined by the data from the present study, our data
suggest that the antiallodynic effect of 2-PMPA in this model
of neuropathic pain may be due to its inhibitory effect on
ectopic afferent discharges. Consistent with this notion, we
observed that similar doses of 2-PMPA attenuated signifi-
cantly the ectopic discharges from injured afferent nerves.
Generation of ectopic discharges from injured afferents is
considered to be one of the important mechanisms underly-
ing chronic neuropathic pain. Na and Ca2 channels are
known to contribute importantly to the generation of ectopic
discharge activity following nerve injury (Matzner and De-
vor, 1994; Xiao and Bennett, 1995). Glutamate has been
implicated in the generation and maintenance of neuropathic
pain because systemic administration of glutamate receptor
antagonists relieves neuropathic pain (Hao and Xu, 1996;
Sutton et al., 1999; Ta et al., 2000). One important source of
glutamate accumulation is likely through the GCP II path-
way. Both NAAG and GCP II are present in the peripheral
nerve (Berger et al., 1995; Berger and Schwab, 1996). There
are several lines of evidence indicating that glutamate in the
peripheral nerve plays a role in nociception. For instance,
glutamate has been shown to be released from the sciatic
nerve during stimulation (DeFeudis, 1971). NMDA, kainate,
and AMPA receptors are located on axons of peripheral
nerves (Carlton et al., 1995). Local peripheral injection of
glutamate and its receptor agonists induces nociceptive re-
flexes (Ault and Hildebrand, 1993a,b), excitation and sensi-
tization of nociceptive afferents (Du et al., 2001), and me-
chanical allodynia and hyperalgesia, which are blocked by
co-injection of selective glutamate antagonists (Carlton et al.,
1995; Zhou et al., 1996). Furthermore, tissue inflammation
also increases production of glutamate in the peripheral tis-
sue and afferent endings, and local administration of NMDA
and non-NMDA receptor antagonists is effective in alleviat-
ing painful conditions (Davidson et al., 1997; Carlton and
Coggeshall, 1999). The role of peripheral glutamate in nerve
injury-induced plasticity and neuropathic pain has not been
documented previously. In the neuroma site, the glutamate
accumulation at the site of nerve injury may also play an
important role in the generation of abnormal discharge ac-
tivity. It is known that activation of ionotropic glutamate
receptors causes Ca2 as well as Na influx (Hollmann and
Heinemann, 1994). Thus, local glutamate buildup may play a
role in the generation of abnormal afferent barrage. We re-
cently have found that both NMDA and kainate receptors are
up-regulated at the site of sciatic nerve ligation (unpublished
data). Thus, local accumulation of glutamate may contribute
to the development of ectopic discharges from injured affer-
ent nerves. The inhibitory action of 2-PMPA on the ectopic
impulse activity from injured peripheral afferents has not
been studied previously. As demonstrated in the present
study, intravenous injection of 50 to 100 mg/kg 2-PMPA
significantly attenuated the ectopic afferent activity gener-
ated from the site of nerve ligation. Thus, in addition to the
inhibitory effect of 2-PMPA on sensitized spinal neurons
caused by nerve injury (Carpenter et al., 2000), the effect of
2-PMPA on the ectopic afferent activity may contribute to its
antiallodynic action by directly reducing nociceptive afferent
inputs to the dorsal horn neurons. Our data indicate that
2-PMPA has a rapid effect on ectopic discharges, which is
consistent with its effect on tactile allodynia. Thus the allo-
dynia produced in this model may be highly dependent on the
ectopic afferent barrage. Alternatively, the effect of intrave-
nous injection of 2-PMPA on ectopic discharges may not
account entirely for its antiallodynic effect. The antiallodynic
effect of 2-PMPA may be a result of its combined central and
peripheral actions. Data from this study provide a new ra-
tionale for the use of GCP II inhibitors as potential analgesic
agents for neuropathic pain treatment.
We found that 2-PMPA selectively attenuated the ectopic
discharge activity from neuromas but did not affect the con-
duction velocity of afferent nerves. Thus, the inhibitory effect
of 2-PMPA on ectopic discharges is due to inhibition of gen-
eration, but not conduction, of afferent nerves. Inhibition of
GCP II by 2-PMPA can decrease glutamate accumulation
and increase NAAG in neurons and brain tissues (Slusher et
al., 1999; Thomas et al., 2000). NAAG is a partial antagonist
at the NMDA receptor and is also a type II metabotropic
receptor agonist with a high degree of specificity for mGluR3
receptors (Neale et al., 2000). Both of these effects may limit
glutamate receptor activation. However, 2-PMPA itself has
no significant affinity for all known glutamate receptors
tested including NMDA, kainate, AMPA, and glutamate
transporters (Slusher et al., 1999). More importantly, de-
creased glutamate availability from NAAG by inhibition of
GCP II could decrease the excitability of the neuroma at the
injured nerve. GCP II is located extensively in Schwann cells
of the peripheral nerve and may be involved in the signaling
between axons and Schwann cells during nerve degeneration
or regeneration following nerve injury (Berger et al., 1995;
Urazaev et al., 2001). At this time, little is known about GCP
II, NAAG, and glutamate metabolism at the site of nerve
injury. We speculate that nerve injury may be associated
with an increased activity of GCP II, which converts NAAG to
glutamate in the Schwann cells. Increased glutamate
Fig. 4. Lack of inhibitory effect of intravenous injection of 100 mg/kg
2-PMPA on the responses of normal afferent nerves (n  10) elicited by
von Frey filaments (VFH) applied to the receptive field of sciatic afferent
nerves in normal rats. Data are presented as means  S.E.M. Receptive
fields of all normal afferent fibers were located on the left hindpaw.
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buildup in the Schwann cells and periaxonal space could
contribute to generation of ectopic discharge activity at the
site of injury. Data from the present study suggest that GCP
II inhibitors may offer a new strategy for the treatment of
neuropathic pain. It should be acknowledged that this is the
first study showing the therapeutic potential and the likely
sites of action of GCP II inhibitors for neuropathic pain. It is
far from clear how decreased glutamate and increased NAAG
contribute to the data obtained in this study. Additional
studies are needed to define the role of local glutamate and
NAAG in the pharmacological actions of 2-PMPA on ectopic
afferent discharges and allodynia associated with neuro-
pathic pain.
In summary, intravenous injection of 2-PMPA attenuated
significantly the allodynia induced by partial sciatic nerve
ligation in rats in a dose-dependent manner. By directly
recording single-unit activity of afferent fibers, we found that
similar doses of 2-PMPA also inhibited the ectopic discharge
activity from the injured nerve site. Therefore, our study
suggests that the analgesic effect of 2-PMPA may be medi-
ated, at least in part, by inhibition of ectopic afferent dis-
charges through decreased glutamate accumulation and in-
creased NAAG at the site of nerve injury.
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